Photoinduced charge transport over branched conjugation pathways: donor–acceptor substituted 1,1-diphenylethene and 2,3-diphenylbutadiene

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence (http://creativecommons.org/licenses/by-nc/3.0/)Photoinduced charge transport in 1,1-diphenylethene and 2,3-diphenylbutadiene functionalized with an electron donating dimethylamino group and an electron accepting cyano group is reported. UV-spectroscopy reveals that in these compounds, which incorporate a cross-conjugated spacer, a direct charge transfer transition is possible. It is shown by application of the generalized Mulliken–Hush approach that introduction of an additional branching point in the π-electron spacer (i.e., when going from the 1,1-diphenylethene to the 2,3-diphenylbutadiene) leads to only a moderate reduction (68–92%) of the electronic coupling between the ground and the charge separated state. The σ-electron system is however likely to be dominant in the photoinduced charge separation process

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19):an investigator-initiated, randomised, open-label, phase 2 trial

Background Almost all patients with malignant mesothelioma eventually have disease progression after first-line therapy. Previous studies have investigated maintenance therapy, but none has shown a great effect. We aimed to assess the efficacy and safety of switch-maintenance gemcitabine in patients with malignant mesothelioma without disease progression after first-line chemotherapy. Methods We did a randomised, open-label, phase 2 trial in 18 hospitals in the Netherlands (NVALT19). We recruited patients aged older than 18 years with unresectable malignant mesothelioma with no evidence of disease progression after at least four cycles of first-line chemotherapy (with platinum and pemetrexed), who had a WHO performance status of 0-2, adequate organ function, and measurable or evaluable disease. Exclusion criteria were active uncontrolled infection or severe cardiac dysfunction, serious disabling conditions, symptomatic CNS metastases, radiotherapy within 2 weeks before enrolment, and concomitant use of any other drugs under investigation. Patients were randomly assigned (1:1), using the minimisation method, to maintenance intravenous gemcitabine (1250 mg/m(2) on days 1 and 8, in cycles of 21 days) plus supportive care, or to best supportive care alone, until disease progression, unacceptable toxicity, serious intercurrent illness, patient request for discontinuation, or need for any other anticancer agent, except for palliative radiotherapy. A CT scan of the thorax or abdomen (or both) and pulmonary function tests were done at baseline and repeated every 6 weeks. The primary outcome was progression-free survival in the intention-to-treat population. Safety was analysed in all participants who received one or more doses of the study drug or had at least one visit for supportive care. Recruitment is now closed; treatment and follow-up are ongoing. This study is registered with the Netherlands Trial Registry, NTR4132/NL3847. Findings Between March 20, 2014, and Feb 27, 2019, 130 patients were enrolled and randomly assigned to gemcitabine plus supportive care (65 patients [50%]) or supportive care alone (65 patients [50%]). No patients were lost to follow-up; median follow-up was 36.5 months (95% CI 34.2 to not reached), and one patient in the supportive care group withdrew consent. Progression-free survival was significantly longer in the gemcitabine group (median 6.2 months [95% CI 4.6-8.7]) than in the supportive care group (3.2 months [2.8-4.1]; hazard ratio [HR] 0.48 [95% CI 0.33-0.71]; p=0.0002). The benefit was confirmed by masked independent central review (HR 0.49 [0.33-0.72]; p=0.0002). Grade 3-4 adverse events occurred in 33 ( 52%) of 64 patients in the gemcitabine group and in ten (16%) of 62 patients in the supportive care group. The most frequent adverse events were anaemia, neutropenia, fatigue or asthenia, pain, and infection in the gemcitabine group, and pain, infection, and cough or dyspnoea in the supportive care group. One patient (2%) in the gemcitabine group died, due to a treatment-related infection. Interpretation Switch-maintenance gemcitabine, after first-line chemotherapy, significantly prolonged progression-free survival compared with best supportive care alone, among patients with malignant mesothelioma. This study confirms the activity of gemcitabine in treating malignant mesothelioma

Quality of life after patient-initiated vs physician-initiated response to symptom monitoring:the SYMPRO-Lung trial

BackgroundPrevious studies using patient-reported outcomes measures (PROMs) to monitor symptoms during and after (lung) cancer treatment used alerts that were sent to the health-care provider, although an approach in which patients receive alerts could be more clinically feasible. The primary aim of this study was to compare the effect of weekly PROM symptom monitoring via a reactive approach (patient receives alert) or active approach (health-care provider receives alert) with care as usual on health-related quality of life (HRQOL) at 15 weeks after start of treatment in lung cancer patients.MethodsThe SYMPRO–Lung trial is a multicenter randomized controlled trial using a stepped wedge design. Stage I-IV lung cancer patients in the reactive and active groups reported PROM symptoms weekly, which were linked to a common alerting algorithm. HRQOL was measured by the EORTC QLQ-C30 at baseline and after 15 weeks. Linear regression analyses and effect size estimates were used to assess mean QOL–C30 change scores between groups, accounting for confounding.ResultsA total of 515 patients were included (160 active group, 89 reactive group, 266 control group). No differences in HRQOL were observed between the reactive and active group (summary score: unstandardized beta [B] = 0.51, 95% confidence interval [CI] = -3.22 to 4.24, Cohen d effect size [ES] = 0.06; physical functioning: B = 0.25, 95% CI = -5.15 to 4.64, ES = 0.02). The combined intervention groups had statistically and clinically significantly better mean change scores on the summary score (B = 4.85, 95% CI = 1.96 to 7.73, ES = 0.57) and physical functioning (B = 7.00, 95% CI = 2.90 to 11.09, ES = 0.71) compared with the control group.ConclusionsWeekly PRO symptom monitoring statistically and clinically significantly improves HRQOL in lung cancer patients. The logistically less intensive, reactive approach may be a better fit for implementation

HIGH-RESOLUTION EXCITED-STATE PHOTOELECTRON SPECTROSCOPY OF JET-COOLED TETRAMETHYLETHYLENE AND 1,1′1,1^{\prime}-BICYCLOHEXYLIDENE

Author Institution: Faculty of Science, Institute of Molecular Chemistry, University of Amsterdam; Debye Institute, Department of Physical Organic Chemistry, Utrecht UniversityThe spectroscopy and photophysics of tetramethylethylene and $1,1^{\prime}$-bicyclohexylidene have been investigated using excited-state photoelectron spectroscopy in combination with multiphoton excitation. Vibronic coupling within the full manifold of the excited singlet states is shown to play a dominant role in determining the spectroscopic properties of these compounds. Although this vibronic coupling inhibits the determination of excited state excitation energies by excitation spectroscopy, it enables at the same time their observation in the photoelectron spectra. As a result, a large number of previously unobserved Rydberg states could be located and assigned. For both molecules ionization from the Rydberg states is observed to be heavily perturbed by ionization from the underlying quasi-continuum of the $(\pi,\pi^{\ast})$ valence state. The photoelectron spectra of $1,1^{\prime}$-bicyclohexylidene reveal that the state around $55000 cm^{-1}$ (6.82 eV), which has previously been assigned as a second valence state, does not show the ionization pattern expected on the basis of previous suggestions made for the character of this state. Based on this observation and on the result of ab initio calculations on various alkylated mono-olefins, configuration mixing between the $(\pi,\pi^{\ast})$ valence state and the $(\pi,3d)$ Rydberg manifold is offered as a possible explanation

Nanodiscs bounded by styrene-maleic acid allow trans-cis isomerization of enclosed photoswitches of azobenzene labeled lipids

Styrene-and-maleic acid (SMA) copolymers behave as amphipathic belts encircling lipids in the form of nanodiscs. It is unclear to what extent the SMA belt affects the order and dynamics of the enclosed lipids. We aimed to obtain insight into this by making use of synthetic azobenzene-labeled phospholipids incorporated into di-16:0 PC nanodiscs. Azobenzene lipids undergo geometric isomerization upon exposure to light at 365 nm, resulting in the formation of cis-isomers that possess a larger cross-sectional area than the trans-isomers. The influence of the lipid properties on the kinetics and extent of isomerization of the azobenzene groups was first tested in large unilamellar vesicles constituted by lipid mixtures with different packing properties of the acyl chains. Fastest isomerization kinetics were found when azolipids were present in membranes supplemented with lysolipids and slowest in those supplemented with di-unsaturated lipids, suggesting that the isomerization rate is sensitive to the lateral pressure profile in the lipid bilayer and hence may be considered a convenient tool to monitor packing properties of lipids enclosed in nanodiscs. When azolipids were incorporated in SMA-bounded nanodiscs, azolipid isomerization was found to take place readily, indicating that SMA polymers behave as rather flexible belts and allow expansion of the enclosed lipid material

Nanodiscs bounded by styrene-maleic acid allow trans-cis isomerization of enclosed photoswitches of azobenzene labeled lipids

Styrene-and-maleic acid (SMA) copolymers behave as amphipathic belts encircling lipids in the form of nanodiscs. It is unclear to what extent the SMA belt affects the order and dynamics of the enclosed lipids. We aimed to obtain insight into this by making use of synthetic azobenzene-labeled phospholipids incorporated into di-16:0 PC nanodiscs. Azobenzene lipids undergo geometric isomerization upon exposure to light at 365 nm, resulting in the formation of cis-isomers that possess a larger cross-sectional area than the trans-isomers. The influence of the lipid properties on the kinetics and extent of isomerization of the azobenzene groups was first tested in large unilamellar vesicles constituted by lipid mixtures with different packing properties of the acyl chains. Fastest isomerization kinetics were found when azolipids were present in membranes supplemented with lysolipids and slowest in those supplemented with di-unsaturated lipids, suggesting that the isomerization rate is sensitive to the lateral pressure profile in the lipid bilayer and hence may be considered a convenient tool to monitor packing properties of lipids enclosed in nanodiscs. When azolipids were incorporated in SMA-bounded nanodiscs, azolipid isomerization was found to take place readily, indicating that SMA polymers behave as rather flexible belts and allow expansion of the enclosed lipid material